Evidence mapPaperPMID 39797465Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2025

Polyproline-Polyornithine Diblock Copolymers with Inherent Mitochondria Tropism.

Camilla Pegoraro, Ekaterina Karpova, Yusuf Qutbuddin, Esther Masiá Sanchis, Pavels Dimitrijevs, Cristián Huck-Iriart, Svetozar Gavrilović, Pavel Arsenyan, Petra Schwille, Carles Felip-León and 3 more

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Multifunctional Polypeptide-Based Nanoconjugates for Targeted Mitochondrial Delivery and Nonviral Gene Therapy.Chemistry of materials : a publication of the American Chemical Society · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Camilla PegoraroPríncipe Felipe Research Center, Polymer Therapeutics Lab., Valencia, 46012, Spain.ORCID https://orcid.org/0000-0003-0347-7763
Ekaterina KarpovaCurapath, Av. Benjamín Franklin, 19, Paterna, Valencia, 46980, Spain.ORCID https://orcid.org/0000-0002-8336-316X
Yusuf QutbuddinMax Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.ORCID https://orcid.org/0000-0003-0054-0608
Esther Masiá SanchisPríncipe Felipe Research Center, Polymer Therapeutics Lab., Valencia, 46012, Spain.ORCID https://orcid.org/0000-0003-2293-0359
Pavels DimitrijevsLatvian Institute of Organic Synthesis, Aizkraukles Street 21, Riga, LV-1006, Latvia.ORCID https://orcid.org/0000-0002-6332-2395
Cristián Huck-IriartExperiments Division, ALBA Synchrotron Light Source, Cerdanyola del Vallès, 08209, Spain.ORCID https://orcid.org/0000-0001-5734-2499
Svetozar GavrilovićMax Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.ORCID https://orcid.org/0000-0002-7710-7864
Pavel ArsenyanLatvian Institute of Organic Synthesis, Aizkraukles Street 21, Riga, LV-1006, Latvia.ORCID https://orcid.org/0000-0001-5875-2799
Petra SchwilleMax Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.ORCID https://orcid.org/0000-0002-6106-4847
Carles Felip-LeónCurapath, Av. Benjamín Franklin, 19, Paterna, Valencia, 46980, Spain.ORCID https://orcid.org/0000-0002-2476-3243
Aroa Duro-CastanoCurapath, Av. Benjamín Franklin, 19, Paterna, Valencia, 46980, Spain.ORCID https://orcid.org/0000-0001-7279-854X
Inmaculada Conejos-SanchezPríncipe Felipe Research Center, Polymer Therapeutics Lab., Valencia, 46012, Spain.ORCID https://orcid.org/0000-0002-4196-0855
María J VicentPríncipe Felipe Research Center, Polymer Therapeutics Lab., Valencia, 46012, Spain.ORCID https://orcid.org/0000-0001-7771-3373

Funding

BioMedPharm VPP-EM-BIOMEDICINA-2022/1-0001Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana NextGeneration EU i+d+I funding through GVA Conselleria Innovació- Pol@Mets. Ref. MFA/2022/065European Regional Development Fund PO FEDER Comunitat Valenciana 2014-2020Fundación Científica Asociación Española Contra el Cáncer INVES211323CONE Junior AECC grantH2020 Marie Skłodowska-Curie Actions H2020-MSCA-ITN-2019 BIOMOLMACS (proposal n° 859416)HORIZON EUROPE Reforming and enhancing the European Research and Innovation system EU-OPENSCREEN IMPULSE (Grant Agreement No. 101132028)Ministerio de Ciencia e Innovación PID2019-108806RB-I00Ministerio de Ciencia e Innovación PID2023-152459OB-I00NCD-SWEET beamline at the ALBA Synchrotron Light source in Barcelona, Spain 2022097124
6 · The paper itself

Abstract

Mitochondria play critical roles in regulating cell fate, with dysfunction correlating with the development of multiple diseases, emphasizing the need for engineered nanomedicines that cross biological barriers. Said nanomedicines often target fluctuating mitochondrial properties and/or present inefficient/insufficient cytosolic delivery (resulting in poor overall activity), while many require complex synthetic procedures involving targeting residues (hindering clinical translation). The synthesis/characterization of polypeptide-based cell penetrating diblock copolymers of poly-L-ornithine (PLO) and polyproline (PLP) (PLO

Indexed as

Drug CarriersMitochondriaPeptidesPolymersAnimalsHumansMiceDrug CarriersPeptidesPolymerspolyprolinecardiolipin‐specific mitochondrial targetingdesign of experiments (doe)membrane remodelingmitochondrial tropismpolypeptide‐based nanoconjugatespolyproline, subcellular organelle targeting

Identifiers

PMID39797465
PMCPMC11854869

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.